SHAREHOLDERS' EQUITY (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
	Mar. 27, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Increase (Decrease) in Shareholders' Equity
Beginning Balance (in shares)				334,402,964
Beginning Balance				$ 5,434.5	$ 5,233.3
Issuance of common stock (in shares)	7,286,432
Issuance of common stock	$ 1,450.0			1,481.0
Common shares issued under share-based compensation plans				29.1	9.6
Settlement of stock options					(3.1)
Repurchases of common shares				(50.0)
Share-based compensation				111.4	60.6
Employee withholding taxes related to share-based awards				(85.8)	(38.5)
Excess tax benefits from share-based compensation				21.7	17.1
Acquisition of noncontrolling interest					(3.3)
Noncontrolling interest from business combinations				4.9
Noncontrolling interest distributions				(7.0)	(0.5)
Total before comprehensive income (loss)		$ 6,939.8	$ 5,275.2	6,939.8	5,275.2
Comprehensive loss:
Net income		51.7	276.4	74.6	378.1
Other comprehensive loss				(549.7)	(419.7)
Comprehensive loss		$ (122.0)	(169.7)	$ (475.1)	(41.6)
Ending Balance (in shares)		343,094,009		343,094,009
Ending Balance		$ 6,464.7	$ 5,233.6	$ 6,464.7	$ 5,233.6
Common Shares
Increase (Decrease) in Shareholders' Equity
Beginning Balance (in shares)				334,400,000	333,000,000
Beginning Balance				$ 8,349.2	$ 8,301.2
Issuance of common stock (in shares)				7,500,000
Issuance of common stock				$ 1,481.0
Common shares issued under share-based compensation plans (in shares)				1,400,000	1,000,000
Common shares issued under share-based compensation plans				$ 75.7	$ 33.2
Repurchases of common shares (in shares)				(200,000)
Repurchases of common shares				$ (6.3)
Total before comprehensive income (loss) (in shares)		343,100,000	334,000,000	343,100,000	334,000,000
Total before comprehensive income (loss)		$ 9,899.6	$ 8,334.4	$ 9,899.6	$ 8,334.4
Comprehensive loss:
Ending Balance (in shares)		343,100,000	334,000,000	343,100,000	334,000,000
Ending Balance		$ 9,899.6	$ 8,334.4	$ 9,899.6	$ 8,334.4
Additional Paid-In Capital
Increase (Decrease) in Shareholders' Equity
Beginning Balance				243.9	228.8
Common shares issued under share-based compensation plans				(46.6)	(23.6)
Settlement of stock options					(3.1)
Share-based compensation				111.4	60.6
Employee withholding taxes related to share-based awards				(85.8)	(38.5)
Excess tax benefits from share-based compensation				21.7	17.1
Acquisition of noncontrolling interest					(1.1)
Total before comprehensive income (loss)		244.6	240.2	244.6	240.2
Comprehensive loss:
Ending Balance		244.6	240.2	244.6	240.2
Accumulated Deficit
Increase (Decrease) in Shareholders' Equity
Beginning Balance				(2,365.0)	(3,278.5)
Repurchases of common shares				(43.7)
Total before comprehensive income (loss)		(2,408.7)	(3,278.5)	(2,408.7)	(3,278.5)
Comprehensive loss:
Net income				70.2	378.6
Ending Balance		(2,338.5)	(2,899.9)	(2,338.5)	(2,899.9)
Accumulated Other Comprehensive Loss
Increase (Decrease) in Shareholders' Equity
Beginning Balance				(915.9)	(132.8)
Total before comprehensive income (loss)		(915.9)	(132.8)	(915.9)	(132.8)
Comprehensive loss:
Other comprehensive loss				(547.5)	(419.2)
Ending Balance		(1,463.4)	(552.0)	(1,463.4)	(552.0)
Valeant Pharmaceuticals International, Inc. Shareholders’ Equity
Increase (Decrease) in Shareholders' Equity
Beginning Balance				5,312.2	5,118.7
Issuance of common stock				1,481.0
Common shares issued under share-based compensation plans				29.1	9.6
Settlement of stock options					(3.1)
Repurchases of common shares				(50.0)
Share-based compensation				111.4	60.6
Employee withholding taxes related to share-based awards				(85.8)	(38.5)
Excess tax benefits from share-based compensation				21.7	17.1
Acquisition of noncontrolling interest					(1.1)
Total before comprehensive income (loss)		6,819.6	5,163.3	6,819.6	5,163.3
Comprehensive loss:
Net income				70.2	378.6
Other comprehensive loss				(547.5)	(419.2)
Comprehensive loss				(477.3)	(40.6)
Ending Balance		6,342.3	5,122.7	6,342.3	5,122.7
Noncontrolling Interest
Increase (Decrease) in Shareholders' Equity
Beginning Balance				122.3	114.6
Acquisition of noncontrolling interest					(2.2)
Noncontrolling interest from business combinations				4.9
Noncontrolling interest distributions				(7.0)	(0.5)
Total before comprehensive income (loss)		120.2	111.9	120.2	111.9
Comprehensive loss:
Net income				4.4	(0.5)
Other comprehensive loss				(2.2)	(0.5)
Comprehensive loss				2.2	(1.0)
Ending Balance		$ 122.4	$ 110.9	$ 122.4	$ 110.9